GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » PB Ratio

Blueprint Medicines (LTS:0HOJ) PB Ratio : 18.19 (As of Apr. 25, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-25), Blueprint Medicines's share price is $85.28. Blueprint Medicines's Book Value per Share for the quarter that ended in Dec. 2024 was $4.69. Hence, Blueprint Medicines's PB Ratio of today is 18.19.

Good Sign:

Blueprint Medicines Corp stock PB Ratio (=18.27) is close to 1-year low of 16.71.

The historical rank and industry rank for Blueprint Medicines's PB Ratio or its related term are showing as below:

LTS:0HOJ' s PB Ratio Range Over the Past 10 Years
Min: 2.8   Med: 6.06   Max: 44.53
Current: 18.22

During the past 12 years, Blueprint Medicines's highest PB Ratio was 44.53. The lowest was 2.80. And the median was 6.06.

LTS:0HOJ's PB Ratio is ranked worse than
95.56% of 1285 companies
in the Biotechnology industry
Industry Median: 2.18 vs LTS:0HOJ: 18.22

During the past 12 months, Blueprint Medicines's average Book Value Per Share Growth Rate was 119.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -34.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -28.20% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Blueprint Medicines was 21.40% per year. The lowest was -56.20% per year. And the median was 13.60% per year.

Back to Basics: PB Ratio


Blueprint Medicines PB Ratio Historical Data

The historical data trend for Blueprint Medicines's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines PB Ratio Chart

Blueprint Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.19 6.19 5.05 42.98 18.50

Blueprint Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.98 19.04 20.92 18.47 18.50

Competitive Comparison of Blueprint Medicines's PB Ratio

For the Biotechnology subindustry, Blueprint Medicines's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's PB Ratio distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's PB Ratio falls into.


;
;

Blueprint Medicines PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Blueprint Medicines's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=85.28/4.688
=18.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Blueprint Medicines  (LTS:0HOJ) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Blueprint Medicines PB Ratio Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines